KALVISTA PHARMACEUTICALS, INC.

(KALV)
  Report
Real-time Estimate Cboe BZX  -  11:42 2022-06-28 am EDT
9.815 USD   -2.44%
06/24KALVISTA PHARMACEUTICALS, INC.(NASDAQGM : KALV) dropped from Russell 2500 Growth Index
CI
06/24KALVISTA PHARMACEUTICALS, INC.(NASDAQGM : KALV) dropped from Russell Small Cap Comp Growth Index
CI
06/24KALVISTA PHARMACEUTICALS, INC.(NASDAQGM : KALV) added to Russell Microcap Value Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

KalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental Allergy

03/22/2022 | 06:01am EDT

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the publication of new data in Clinical & Experimental Allergy characterizing KVD900, a novel, potent and selective oral inhibitor of plasma kallikrein, a critical mediator of attacks in patients with hereditary angioedema (HAE). In this new publication, orally administered KVD900 was shown to be quickly absorbed and provided rapid and near-complete inhibition of plasma kallikrein and strong suppression of kallikrein-kinin system activation in patients with HAE.

“Based on these results, on-demand administration of KVD900 is further demonstrated to block the generation of plasma kallikrein and bradykinin in HAE patient plasma and thereby may provide an opportunity to halt and reverse HAE attacks,” said Andrew Crockett, Chief Executive Officer of KalVista. “These data provide the underlying basis for the clinical results we reported for our phase 2 trial of KVD900 in on-demand treatment of HAE attacks, and further support our ongoing phase 3 KONFIDENT trial for KVD900 in the same indication.”

Additional details can be found in the manuscript, which is available at: http://doi.org/10.1111/cea.14122. Clinical & Experimental Allergy is the official journal of the British Society for Allergy & Clinical Immunology.

About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks and has initiated the Phase 3 KONFIDENT clinical trial. KVD824 is in development for prophylactic treatment of HAE, with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

For more information about KalVista, please visit www.kalvista.com.
For more information on the KVD900 HAE on-demand Phase 3 KONFIDENT study, please visit www.konfidentstudy.com.
For more information on the KVD824 HAE prophylaxis Phase 2 KOMPLETE study, please visit www.kompletestudy.com.

Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including the potential impact of COVID-19, that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 3 KONFIDENT and Phase 2 KOMPLETE clinical trials, and to obtain regulatory approvals for KVD900, KVD824 and other candidates in development, the ability of KVD900, KVD824 and other candidates in development to treat HAE or DME, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2021, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.


© Business Wire 2022
All news about KALVISTA PHARMACEUTICALS, INC.
06/24KALVISTA PHARMACEUTICALS, INC.(NASDA : KALV) dropped from Russell 2500 Growth Index
CI
06/24KALVISTA PHARMACEUTICALS, INC.(NASDA : KALV) dropped from Russell Small Cap Comp Growth In..
CI
06/24KALVISTA PHARMACEUTICALS, INC.(NASDA : KALV) added to Russell Microcap Value Index
CI
06/24KALVISTA PHARMACEUTICALS, INC.(NASDA : KALV) added to Russell Small Cap Comp Value Index
CI
06/24KALVISTA PHARMACEUTICALS, INC.(NASDA : KALV) dropped from Russell 2000 Growth Index
CI
06/24KALVISTA PHARMACEUTICALS, INC.(NASDA : KALV) added to Russell 2000 Value Index
CI
06/24KALVISTA PHARMACEUTICALS, INC.(NASDA : KALV) dropped from Russell 3000 Growth Index
CI
06/24KALVISTA PHARMACEUTICALS, INC.(NASDA : KALV) added to Russell 3000 Value Index
CI
06/24KALVISTA PHARMACEUTICALS, INC.(NASDA : KALV) added to Russell 3000E Value Index
CI
06/24KALVISTA PHARMACEUTICALS, INC.(NASDA : KALV) dropped from Russell 3000E Growth Index
CI
More news
Analyst Recommendations on KALVISTA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -84,6 M - -
Net cash 2022 168 M - -
P/E ratio 2022 -2,91x
Yield 2022 -
Capitalization 247 M 247 M -
EV / Sales 2022 -
EV / Sales 2023 65,4x
Nbr of Employees 70
Free-Float 97,2%
Chart KALVISTA PHARMACEUTICALS, INC.
Duration : Period :
KalVista Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KALVISTA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 10,06 $
Average target price 41,67 $
Spread / Average Target 314%
EPS Revisions
Managers and Directors
T. Andrew Crockett Chief Executive Officer & Director
Benjamin L. Palleiko Chief Financial & Business Officer
Martin W. Edwards Chairman
Edward P. Feener Chief Scientific Officer
Paul K. Audhya Chief Medical Officer
Sector and Competitors